TY - JOUR
T1 - The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats
AU - Granados-Soto, V.
AU - Argüelles, C. F.
AU - Rocha-González, H. I.
AU - Godínez-Chaparro, B.
AU - Flores-Murrieta, F. J.
AU - Villalón, C. M.
N1 - Funding Information:
Authors greatly appreciate the bibliographic and technical assistance of B.Sc. Héctor Vázquez and M.Sc. Guadalupe C. Vidal-Cantú, respectively. Héctor I. Rocha-González and Beatriz Godínez-Chaparro are CONACYT fellows. This study was partially supported by Conacyt grants 59879 (VG-S) and 60789 (CMV).
PY - 2010/1/20
Y1 - 2010/1/20
N2 - This study assessed the possible antinociceptive role of peripheral 5-HT1 receptor subtypes in the rat formalin test. Rats were injected into the dorsum of the hind paw with 50 μl of diluted formalin (1%). Nociceptive behavior was quantified as the number of flinches of the injected paw. Reduction of flinching was considered as antinociception. Ipsilateral, but not contralateral, peripheral administration of the 5-HT1 receptor agonists R(+)-UH-301 (5-HT1A; 0.1-3 μg/paw), CGS-12066A (5-HT1B; 0.01-0.3 μg/paw), GR46611 (5-HT1B/1D; 0.3-10 μg/paw), BRL54443 (5-HT1E/1F; 3-300 μg/paw) or LY344864 (5-HT1F; 3-300 μg/paw) significantly reduced formalin-induced flinching. The corresponding vehicle was devoid of any effect by itself. The local antinociceptive effect of R(+)-UH-301 (0.3 μg/paw) was significantly reduced by WAY-100635 (30-100 μg/paw; a 5-HT1A receptor antagonist). Moreover, the antagonists GR55562 (30-100 μg/paw; 5-HT1B/D) or SB224289 (30-100 μg/paw; 5-HT1B) dose-dependently reduced the antinociceptive effect of CGS-12066A (0.3 μg/paw) whereas GR55562 (30-100 μg/paw) or BRL15572 (30-100 μg/paw, 5-HT1D) reduced the antinociceptive effect of GR46611 (0.3 μg/paw). Interestingly, the effects of BRL54443 and LY344864 (300 μg/paw each) were partially reduced by methiothepin, but not by the highest doses of WAY-100635, SB224289 or BRL15572. The above antagonists did not produce any effect by themselves. These results suggest that peripheral activation of the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F and, probably, 5-HT1E receptor subtypes leads to antinociception in the rat formalin test. Thus, the use of selective 5-HT1 receptor agonists could be a therapeutic strategy to reduce inflammatory pain.
AB - This study assessed the possible antinociceptive role of peripheral 5-HT1 receptor subtypes in the rat formalin test. Rats were injected into the dorsum of the hind paw with 50 μl of diluted formalin (1%). Nociceptive behavior was quantified as the number of flinches of the injected paw. Reduction of flinching was considered as antinociception. Ipsilateral, but not contralateral, peripheral administration of the 5-HT1 receptor agonists R(+)-UH-301 (5-HT1A; 0.1-3 μg/paw), CGS-12066A (5-HT1B; 0.01-0.3 μg/paw), GR46611 (5-HT1B/1D; 0.3-10 μg/paw), BRL54443 (5-HT1E/1F; 3-300 μg/paw) or LY344864 (5-HT1F; 3-300 μg/paw) significantly reduced formalin-induced flinching. The corresponding vehicle was devoid of any effect by itself. The local antinociceptive effect of R(+)-UH-301 (0.3 μg/paw) was significantly reduced by WAY-100635 (30-100 μg/paw; a 5-HT1A receptor antagonist). Moreover, the antagonists GR55562 (30-100 μg/paw; 5-HT1B/D) or SB224289 (30-100 μg/paw; 5-HT1B) dose-dependently reduced the antinociceptive effect of CGS-12066A (0.3 μg/paw) whereas GR55562 (30-100 μg/paw) or BRL15572 (30-100 μg/paw, 5-HT1D) reduced the antinociceptive effect of GR46611 (0.3 μg/paw). Interestingly, the effects of BRL54443 and LY344864 (300 μg/paw each) were partially reduced by methiothepin, but not by the highest doses of WAY-100635, SB224289 or BRL15572. The above antagonists did not produce any effect by themselves. These results suggest that peripheral activation of the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F and, probably, 5-HT1E receptor subtypes leads to antinociception in the rat formalin test. Thus, the use of selective 5-HT1 receptor agonists could be a therapeutic strategy to reduce inflammatory pain.
KW - 5-HT1 receptor subtypes
KW - hyperalgesia
KW - inflammatory pain
UR - http://www.scopus.com/inward/record.url?scp=71949117509&partnerID=8YFLogxK
U2 - 10.1016/j.neuroscience.2009.10.020
DO - 10.1016/j.neuroscience.2009.10.020
M3 - Artículo
C2 - 19837141
SN - 0306-4522
VL - 165
SP - 561
EP - 568
JO - Neuroscience
JF - Neuroscience
IS - 2
ER -